Tigris Pharmaceuticals
Bonita Springs · Founded 2005
About Tigris Pharmaceuticals
Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.
Company Facts
- Founded: 2005
- Legal name: Tigris Pharmaceuticals, Inc
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $32.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Sep 2010)
- Website: tigrispharma.com
- Phone: 239.444.5400
Canonical: https://fsome.com/organization/tigris-pharmaceuticals-8427238 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.